Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongnaoyin
- Development stage
- Preclinical
- Lead developer
- Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Tongnaoyin (通脑饮) is a Traditional Chinese Medicine (TCM) formula currently undergoing clinical investigation for the treatment of cerebral infarction. Developed and utilized by institutions such as the Jiangsu Province Hospital of Traditional Chinese Medicine, it is believed to exert its therapeutic effects through complex mechanisms, including the activation of the Androgen Receptor (AR) and modulation of various signaling pathways like IL-17, PI3K-Akt, and prolactin. Network pharmacology and molecular docking studies have identified key active components such as β-sitosterol, kaempferol, and carotenoids, which are thought to contribute to its pharmacological actions.
- Other names
- 通脑饮
Beyond the preview
Go deeper on Tongnaoyin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tongnaoyin.